The potential of exosomes as an alternative delivery vector for the CRISPR/Cas9 components encourages Creative Biolabs to present its exosome engineering strategies.

Considering a recently featured article by NIH introducing the therapeutic effects of NSC-derived exosomes in cerebral ischemia, Creative Biolabs updates its service portfolio related to stem cell-derived exosomes.

Creative Biolabs provides advanced analytics and exosome engineering solutions to drive exosomal targeting delivery studies.

To extend the upstream production and downstream applications of exosomes, Creative Biolabs collects new strategies and technologies to prompt exosome-based biomolecule delivery, including drugs and vaccines.

Creative Biolabs is looking to help exosome researchers and streamline their projects, with the public launch of its innovative Nanosight™ platform, which enables intuitive and efficient exosomal isolation, purification, and characterization.

Creative Biolabs, a leading life science company specialized in exosome research services, has been one of the top players of growing exosome market size and trend based on its full-scale exosome sampling, analysis, and manufacturing services.

To better aid SARS-CoV-2 drug discovery, Creative Biolabs updates its exosome services for displaying ACE2 variants on the surface of small extracellular vesicles.

With the identified role of lipids in exosome biology and intercellular communication, Creative Biolabs highlights the importance of lipidomics in exosome research by providing complete lipidomic profiling services.

Since exosomes and their molecular contents are explored as biomarkers and diagnostic tools, Creative Biolabs offers further support to exosome-related research, especially for diagnostic applications.